About Human Papillomavirus Type 18 (HPV18) E7 Recombinant Protein

Human Papillomavirus Type 18 (HPV18) is a high-risk papillomavirus strongly associated with cervical cancer, anogenital cancers, and other HPV-associated malignancies. The E7 protein is a major viral oncoprotein that drives malignant transformation by binding and inactivating members of the retinoblastoma (pRb) tumor suppressor family, resulting in deregulated cell-cycle progression and uncontrolled cellular proliferation. Persistent expression of E7 is essential for the development and maintenance of HPV-associated cancers, making it a key target for therapeutic vaccine development, cancer immunotherapy, and tumor immunology research.

eEnzyme's Human HPV18 E7 Recombinant Protein is produced for research use and is suitable for studies of HPV oncogenesis, T-cell immune responses, antibody generation, ELISA development, Western blotting, epitope mapping, and therapeutic vaccine evaluation. This recombinant protein provides a valuable reagent for investigating HPV18-associated malignancies, host immune responses, and the development of next-generation immunotherapies targeting HPV-driven cancers.

Applications

Biological Significance of HPV18 E7

HPV18 E7 is one of the principal viral oncoproteins responsible for HPV-induced carcinogenesis. By inactivating the pRb tumor suppressor pathway, E7 promotes uncontrolled cell proliferation and contributes to the initiation and maintenance of HPV-associated tumors. Because E7 is continuously expressed in many HPV-positive cancers, it remains one of the most important tumor-associated antigens for therapeutic vaccine development and cancer immunotherapy. The HPV18 E7 Recombinant Protein provides a valuable research tool for studying HPV biology, antigen-specific immune responses, and the development of novel therapeutic strategies against HPV-associated malignancies.